NEW YORK, Aug. 4 (GenomeWeb News) -- Biotech company CeMines, of Evergreen,
"We have the existing infrastructure necessary to enable CeMines to immediately accelerate the growth of sales from our existing product line of research tools, including antibodies, cDNA, and mRNA, and at the same time commence with our market introduction of a new family of products targeted at establishing CeMines as a premier brand in drug discovery and other markets," Roger Attick, president and CEO of CeMines said in an official statement.
Founded in 2000, the company has primarily uses gene regulation technology to help develop diagnostics and therapeutics for cancer. In June, the company expanded its diagnostics and therapeutics division and moved it to a new facility in
CeMines is attempting to commercialize its patent-pending Molecular FingerPrinting technology to aid in developing early-stage diagnostics and targeted therapeutics, the company said.